Imagion Biosystems Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Imagion Biosystems has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Proulx	Executive Chairman	9.6yrs	AU$409.30k	0.44% A$ 3.9k
Ward Detwiler	Chief Business Officer	less than a year	no data	no data
Melanie Leydin	Non-Executive Director & Company Secretary	less than a year	no data	no data

0.7yrs

Average Tenure

Experienced Management: IBX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Proulx	Executive Chairman	9.6yrs	AU$409.30k	0.44% A$ 3.9k
Melanie Leydin	Non-Executive Director & Company Secretary	less than a year	no data	no data
Brett Mitchell	Non-Executive Director	less than a year	no data	1.49% A$ 13.0k

0.3yrs

Average Tenure

Experienced Board: IBX's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.

Imagion Biosystems Management

Management criteria checks 0/4

Key information

Recent management updates

Imagion Biosystems Limited Announces Board Changes

No independent directors

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

No independent directors

Recent updates

New minor risk - Shareholder dilution

Imagion Biosystems Limited Announces Board Changes

No independent directors

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.35 loss in FY 2022)

New major risk - Share price stability

No independent directors

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

New major risk - Market cap size

First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.005 loss in 1H 2022)

New major risk - Financial position

New minor risk - Financial data availability

Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman

New minor risk - Share price stability

Imagion Biosystems Limited Announces CEO Changes

New major risk - Market cap size

Imagion Biosystems Limited Reports Positive Clinical Data At Breast Cancer Symposium

No independent directors

First half 2022 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in 1H 2021)

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 25, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Imagion Biosystems Limited Announces First Patient Enrolled in the MagSense® HER2 Breast Cancer Phase I First-In-Human Study

Imagion Biosystems Limited Receives CSIRO Grant for Prostate Cancer Project

Full year 2020 earnings released: AU$0.007 loss per share (vs AU$0.01 loss in FY 2019)

New 90-day high: AU$0.21

New 90-day high: AU$0.21

Imagion Biosystems Limited Provides First-In-Human Study Update - Study Open for Enrolment

Imagion Biosystems Limited Announces Change of Company Secretary

Imagion Biosystems Limited announced that it expects to receive AUD 6 million in funding

Imagion Biosystems Limited Appoints Geoff Hollis as CFO

Imagion Biosystems Announces HREC Approval for Phase I Study

First half earnings released

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure